PMID- 31179336
OWN - NLM
STAT- MEDLINE
DCOM- 20191125
LR  - 20220408
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2019
DP  - 2019
TI  - Utilization and Dose Optimization of Angiotensin-Converting Enzyme Inhibitors 
      among Heart Failure Patients in Southwest Ethiopia.
PG  - 9463872
LID - 10.1155/2019/9463872 [doi]
LID - 9463872
AB  - BACKGROUND: Optimal use of angiotensin-converting enzyme inhibitors (ACEIs) is 
      crucial to improve the treatment outcome in heart failure patients. However, 
      little is known about the optimal use of ACEIs among heart failure patients in 
      our setting. Therefore, our study aimed to investigate the utilization and 
      optimal dosing of ACEIs and associated factors in heart failure patients. METHOD: 
      A cross-sectional study was conducted on randomly selected patients with heart 
      failure between February 2016 and June 2016 at ambulatory care clinic of Jimma 
      University Medical Center, Ethiopia. Data were collected through patient 
      interview and review of medical records. Binary logistic regression analysis was 
      done to identify factors associated with utilization and optimal dosing of ACEIs. 
      RESULTS: A total of 308 patients were included in the final analysis of this 
      study. The mean (+/-standard deviation) age of the patients was 52.3 +/-15.5 years. 
      Out of the total, 74.7% of the patients were receiving ACEIs. Among the patients 
      who were receiving ACEIs, only 35.7% were taking optimal dose. New York Heart 
      Association (NYHA) class III (Adjusted odds ratio (AOR):0.12, 95% confidence 
      interval (CI):0.02-0.98), valvular heart disease (AOR: 0.27, 95% CI: 0.13-0.56), 
      hypertension (AOR: 5.82, 95% CI: 2.16-15.71), and diabetes mellitus (AOR: 3.84, 
      95% CI: 1.07-13.86) were significantly associated with the use of ACEIs, whereas 
      age >/=65 (AOR: 2.61, 95%CI: 1.20-5.64), previous hospitalization for heart failure 
      (AOR: 2.08, 95%CI: 1.11-3.92), diuretic use (AOR: 5.60, 95%CI: 2.75-11.40), and 
      dose of furosemide >40mg (AOR: 9.80, 95%CI: 3.00-31.98) were predictors of 
      suboptimal dosing of ACEIs. CONCLUSION: Although majority of patients were 
      receiving ACEIs, only about one-third were using optimal dosage. Valvular heart 
      disease and NYHA class III were negatively associated with the use of ACEIs while 
      previous hospitalization for heart failure, old age, diuretic use, and diuretic 
      dose were predictors of suboptimal dosing of ACEIs. Therefore, more effort needs 
      to be done to minimize the potentially modifiable risk factors of suboptimal use 
      of ACEIs therapy in heart failure patients.
FAU - Niriayo, Yirga Legesse
AU  - Niriayo YL
AUID- ORCID: 0000-0002-6943-753X
AD  - Department of Clinical Pharmacy, School of Pharmacy, College of Health Sciences, 
      Mekelle University, Mekelle, Tigray, Ethiopia.
FAU - Kumela, Kabaye
AU  - Kumela K
AUID- ORCID: 0000-0001-6453-9118
AD  - Department of Clinical Pharmacy, School of Pharmacy, Faculty of Health Sciences, 
      Jimma University, Jimma, Oromyia, Ethiopia.
FAU - Gidey, Kidu
AU  - Gidey K
AUID- ORCID: 0000-0002-7363-1327
AD  - Department of Clinical Pharmacy, School of Pharmacy, College of Health Sciences, 
      Mekelle University, Mekelle, Tigray, Ethiopia.
FAU - Angamo, Mulugeta Tarekegn
AU  - Angamo MT
AD  - Department of Clinical Pharmacy, School of Pharmacy, Faculty of Health Sciences, 
      Jimma University, Jimma, Oromyia, Ethiopia.
AD  - Division of Pharmacy, School of Medicine, University of Tasmania, Australia.
LA  - eng
PT  - Journal Article
DEP - 20190424
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*administration & dosage
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus/drug therapy
MH  - *Drug Utilization
MH  - Ethiopia
MH  - Female
MH  - Heart Failure/*drug therapy
MH  - Heart Valve Diseases/drug therapy
MH  - Hospitalization
MH  - Humans
MH  - Hypertension/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Odds Ratio
MH  - Outpatient Clinics, Hospital
MH  - Risk Factors
MH  - Treatment Outcome
PMC - PMC6507240
EDAT- 2019/06/11 06:00
MHDA- 2019/11/26 06:00
PMCR- 2019/04/24
CRDT- 2019/06/11 06:00
PHST- 2018/11/29 00:00 [received]
PHST- 2019/04/17 00:00 [accepted]
PHST- 2019/06/11 06:00 [entrez]
PHST- 2019/06/11 06:00 [pubmed]
PHST- 2019/11/26 06:00 [medline]
PHST- 2019/04/24 00:00 [pmc-release]
AID - 10.1155/2019/9463872 [doi]
PST - epublish
SO  - Biomed Res Int. 2019 Apr 24;2019:9463872. doi: 10.1155/2019/9463872. eCollection 
      2019.